If you purchased certain Similasan, CVS, or Walgreens branded eye drops in the U.S. at any time from September 11, 2017, until February 20, 2025, you could be eligible to receive a payment of $2.50 per eligible product, subject to caps if you do not have proof of purchase and pro rata increase or decrease per the terms of the settlement, from a new $3.575 million class action settlement. Similasan Corporation has settled a class action lawsuit after allegations that it deceptively labeled and advertised its homeopathic eye products. Defendant denies these allegations.
Similasan settled the $3,575,000 class action lawsuit over allegations that its eye drops were deceptively labeled and advertised as homeopathic when the Covered Products had not secured the appropriate approvals from the Federal Food and Drug Administration (“FDA”), were not manufactured according to Current Good Manufacturing Practices, were misleadingly marketed as “sterile,” and failed to disclose the risk of silver sulfate.
What is the Total Settlement Amount?
Similasan has agreed to pay $3,575,000 to settle the class action lawsuit.
How Do I Qualify For a Payout?
To potentially qualify for a payout, you must have purchased any of the Covered Products included in the class action settlement, for personal use and not for resale from September 11, 2017, until February 20, 2025, the preliminary approval date for the Similasan settlement.
Which Similasan Eye Drops Are Included in the Settlement?
The following Similasan and Private Label eye drops may be included in the class action for a payout if you bought them in the U.S. between September 11, 2017, and February 20, 2025: